Background
==========

Sickle cell disease (SCD) has become one of the most studied inherited human diseases,[@b1-vhrm-14-199] although the condition has been described over a century ago.[@b2-vhrm-14-199] The clinical manifestations fall largely into two sub-phenotypes, defined by hyper-hemolysis and vaso-occlusion.[@b3-vhrm-14-199] The multiple pleiotropic effects of the abnormal hemoglobin S production in sickle cell disease usually range from vaso-occlusive crisis (VOC), pulmonary hypertension to osteonecrosis, stroke and leg ulcers, despite being caused by a single point mutation in the HBB gene.[@b4-vhrm-14-199]--[@b6-vhrm-14-199] Among the determinants of SCD, VOC, the hallmark of SCD, is unique, with high prevalence, leading to morbidities, complications and mortalities in affected persons.[@b7-vhrm-14-199],[@b8-vhrm-14-199]

The disease is usually characterized by the production of erythrocytes with increased tendency for lysis and adhesion.[@b9-vhrm-14-199] The pathophysiology of SCD is linked with adhesion of sickle erythrocytes, leukocytes and platelets to adhesive molecules on activated cells, which are found mainly in the endothelium of postcapillary venules.[@b10-vhrm-14-199] The release of free heme resulting from chronic intravascular hemolysis binds to nitric oxide (NO), causing its depletion, followed by vasoconstriction and inflammation.[@b3-vhrm-14-199] Moreover, in cases such as the priapism, plasma hemoglobin released by intravascular hemolyzed sickle red blood cells depletes NO, thereby reducing its bioavailability in the erectile tissue. Consequently, the normal balance of smooth muscle tone is skewed toward vasoconstriction.[@b11-vhrm-14-199]--[@b13-vhrm-14-199] The substrate for NO production, L-arginine is destroyed by arginase (liberated by lysed erythrocytes), providing another mechanism for deficiency of endothelial NO.[@b14-vhrm-14-199]

NO is a soluble gas produced by endothelial cells,[@b15-vhrm-14-199] which is a known endogenous potent vasodilator[@b16-vhrm-14-199]--[@b21-vhrm-14-199] and has blood flow regulatory effect.[@b22-vhrm-14-199],[@b23-vhrm-14-199] NO excites soluble guanylyl cyclase (sGC) in the cavernosal smooth muscle, which in turn triggers increased synthesis of cyclic GMP (cGMP), thus providing the main signal for smooth muscle relaxation.[@b24-vhrm-14-199] Downstream homeostatic vascular functions of NO such as inhibition of platelet activation among others are impaired when there is a reduced endothelial NO bioavailability in sickle cell disease patients.[@b25-vhrm-14-199] NO is also known to be the primary mediator of penile smooth muscle relaxation, which leads to normal erectile function.[@b26-vhrm-14-199]

The relative levels of NO, which is responsible in part for maintaining normal vasomotor tone in SCD patients, during different clinical phases and in SCD complications, seem not clear.[@b27-vhrm-14-199] A study conducted by Rees et al[@b28-vhrm-14-199] reported that NO metabolite (NOx) levels are high in patients with SCD. Our recent study conducted in Accra, Ghana, demonstrated that there is no significant difference in NO levels between the comparison group and SCD patients in the steady state as well as those in the postcrisis state.[@b29-vhrm-14-199] The current study aimed at determining the relative plasma NOx levels among patients with SCD complications including VOC, leg ulcers and priapism in the same population in the Greater Accra Region of Ghana.

Methods
=======

Study setting and study population
----------------------------------

This study was a case--control cross-sectional one, conducted at the Korle Bu Teaching Hospital in the Greater Accra Region of Ghana from February to July, 2014. The cases (SCD patients) and comparison group were recruited from the Center for Clinical Genetics (Sickle Cell Clinic) and Accra Area Blood Center for National blood transfusion, respectively. The study involved a total of 694 participants, including 148 comparison group HbAA, 208 HbSS SCD patients in steady state, 82 HbSC SCD patients in steady state, 156 HbSS SCD patients in VOC, 34 HbSC SCD patients in VOC, 34 HbSS SCD patients in post VOC, 21 HbSS SCD patients with leg ulcers and 11 HbSS SCD patients with priapism. The study protocol was approved by the Ethical and Protocol Review Committee of University of Ghana Medical School. Written informed consents were obtained from all participants and study subjects before samples were obtained. Consent was also sought from the parents/guardians of the children recruited into the study by signing a written informed consent agreement.

Inclusion criteria
------------------

SCD patients ranging in age from 15 and 65 years who had not used nitrite or nitrate-containing medications at least 2 weeks before the sample was taken, were included.

Exclusion criteria
------------------

Patients with renal failure (serum creatinine \>2 mg/dL), pulmonary edema, cardiogenic shock, history of myocardial infarction in the last 6 months, diabetes mellitus, congestive heart failure, a cerebrovascular accident in the last 6 months, acute asthma, or angina pectoris were excluded from the study.

Patients' selection criteria
----------------------------

Steady state was defined clinically as a patient who had been well and had not been in any crisis for at least 2 weeks. VOC was also clinically defined as pains in the bones, muscles and joints that were not due to any other cause and required parenteral analgesia and thus, admittance to the Sickle Cell Center for some hours. Again, leg ulcer was defined as a defect in the skin below the level of the knee and above the foot which persisted for 6 weeks or more. Priapism was also defined as a purposeless, persistent penile erection, particularly unaccompanied by any stimulation or sexual desire, which usually lasted for more than 6 hours. Post VOC was defined as 3 days after crises when patients experienced no pain in the bones and muscles. Patients with crises were followed to the post VOC crises. Patients with history of priapism were those recruited in the current study.

Blood sampling and laboratory measurements
------------------------------------------

Five milliliters of venous blood sample was collected from each of the study participants into ethylendiaminetetracetic acid (EDTA) tubes. Aliquot of 2.5 mL of the blood sample was processed into plasma and stored at −80°C. A full blood count (FBC) was done with 2.5 mL of the blood sample within 2 hours of sample collection using Labsystems Multiskan MS (Amersham Bioscience Ltd, Little Chalfont, UK). An assay which relied on a diazotization reaction originally described by Griess test was used to measure nitrite.[@b30-vhrm-14-199] The Griess Reagent System is based on the chemical reaction which uses sulfanilamide and *N*-L-naphthyl ethylenediamine dihydrochloride (NED) under acidic (phosphoric acid) conditions. This system is able to detect nitrite in a variety of biological and experimental liquid matrices such as plasma. The average absorbance of the triplicates of each experimental sample was recorded. The nitrite concentration (Y) of each experimental sample was determined by comparison to the Nitrite Standard reference curve. In this case the formula: Y=0.0185X+0.106, as generated from the standard curve was used, where X is the average absorbance of the experimental sample.

Data analysis
-------------

The data obtained were stored and analyzed using SPSS version-20 software (IBM Corporation, Armonk, NY, USA). Frequency table were generated for nominal and ordinal variables. The results were expressed as mean plus or minus standard deviation (mean ± SD). The Kruskal--Wallis test was used to compare differences in mean values among SCD patients in steady state and VOC as well as those with leg ulcers and priapism with the healthy comparison group. Dunn's test was done as a post hoc analysis for multiple comparisons. Statistical significance was considered at *P*\<0.05.

Results
=======

Of the 546 SCD patients with and without complication recruited in the study, 430 had the HbSS genotype, while 116 had HbSC genotype. There were more male (n=349) SCD patients than females (n=345) in this study. The difference was not significant (*P*\>0.05). The general characteristics of the SCD patients and the healthy comparison group are summarized in [Table 1](#t1-vhrm-14-199){ref-type="table"}.

Nox levels in different states of SCD patients
----------------------------------------------

The mean plasma NOx levels in SCD patients are illustrated in [Table 2](#t2-vhrm-14-199){ref-type="table"}. The plasma NOx levels were lower in SCD patients with complications compared with those at the steady state, as well as SCD in the immediate postcrises state. However, the level was higher in the HbAA comparison group. The mean level of plasma NOx increased after the immediate post VOC. Among the clinical sub-phenotype studied, patients with leg ulcers had relatively lower levels compared with SCD patients with priapism.

Discussion
==========

NO is a major endothelial-derived relaxing factor in normal physiology of the vasculature and plays a central role in vascular homeostasis.[@b31-vhrm-14-199] Thus, its role in SCD and associated complications cannot be overemphasized. The significantly low plasma NOx levels recorded in the SCD patients with complications (HbSS VOC, HbSC VOC, HbSS leg ulcers and HbSS priapism) in comparison to asymptomatic SCD patients (HbSS steady state and HbSS postcrisis state) and the comparison group, could partly be the participation of NO in the compensatory response to chronic vascular injury in these SCD patients,[@b32-vhrm-14-199] especially those in VOC. This is evident in case reports from other countries where NOx levels were higher in SCD patients in steady states.[@b20-vhrm-14-199],[@b29-vhrm-14-199],[@b33-vhrm-14-199],[@b34-vhrm-14-199]

Conditions including intravascular hemolysis that interfere with NO bioavailability and vasoconstriction might have partly contributed to the lower levels of plasma NOx recorded in the SCD patients with complications.[@b25-vhrm-14-199],[@b35-vhrm-14-199] The clinical presentation of SCD which is due to VOC episodes resulting from polymerization of deoxygenated Hb-S and leading to the formation of sickled red cells, has been reported in a previous study.[@b36-vhrm-14-199] The simultaneous release of erythrocyte arginase during hemolysis[@b14-vhrm-14-199] could limit the availability of arginine to NO, thus contributing to a deficiency of NO.[@b37-vhrm-14-199] The degree of hemolysis encountered in both SCD patients in the immediate postcrises state and steady state SCD patients, may not be as severe as what would have been observed in clinical complications of SCD such as VOC to limit the bioavailability of NO substrate, for NOx depletion. This partly, might have accounted for the observed similar levels of NOx in these two study groups (HbSS post VOC and HbSS steady state).

Observation from this study also suggests that severity of SCD complications may, in part, be related to the degree of NO depletion or the plasma level of NOx as a contribution to the clinical complications suffered by patients with SCD. Although HbSC disease symptoms are similar to those of homozygous (SS) sickle cell such as VOC episodes,[@b38-vhrm-14-199] it presents with milder severity and less frequency.[@b38-vhrm-14-199],[@b39-vhrm-14-199] This might explain in part the relatively lower level of NOx observed in patients with HbSS VOC as well as the higher number of HbSS VOC patients seen in this study, compared with HbSC VOC patients.

Again, findings from this study on the level of NOx among SCD patients with VOC are in line with earlier work conducted by Morris et al[@b20-vhrm-14-199] who also reported that low NOx levels consistently rose in SCD patients with VOC during hospitalization and returned to a steady state value at the time of discharge. Blood plasma levels of L-arginine are depressed in patients with SCD, particularly during VOC and acute chest syndrome, and these levels vary inversely with pain symptoms.[@b33-vhrm-14-199],[@b36-vhrm-14-199] NO-dependent blood flow is impaired in SCD patients.[@b27-vhrm-14-199],[@b40-vhrm-14-199],[@b41-vhrm-14-199] Several studies have indicated the improvement of SCD and associated complications using arginine therapy,[@b42-vhrm-14-199]--[@b44-vhrm-14-199] due to the failure of NO-based therapeutic effect.[@b45-vhrm-14-199],[@b46-vhrm-14-199] Thus, arginine supplementation may be required in the SCD patients with complications studied, especially those with VOC.

Although reports are varied, some investigators have found low levels of NOx (nitrate and nitrite) in patients with SCD, and these reduced levels are consistent with impaired endothelial generation of NO, and its subsequent reactions with hemoglobin and oxygen.[@b22-vhrm-14-199] NO may have a natural effect of vasodilation on smooth muscle vasculature, anti-inflammatory effects and platelet aggregation inhibition.[@b46-vhrm-14-199] Our study had some limitations. Information on malaria in the SCD patients was not obtained, as malaria is also thought to cause hemolysis, thus, dysregulating the arginine-NO pathway. Also, we could not measure plasma arginine levels in the patients. Nonetheless, the findings add to the body of literature concerning NOx levels in SCD sub-phenotypes.

Conclusions
===========

This study showed lower plasma NOx levels in SCD patients with complications such as VOC, priapism and leg ulcers. The levels were however, higher during the immediate post crisis period. Generally, levels of NOx in the comparison group were higher as compared to the SCD patients with or without complications.
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###### 

General characteristics of SCD patients

  Category               Mean age ± SD, years   Gender       *P*-value   
  ---------------------- ---------------------- ------------ ----------- ---------
  HbAA                   31.9±10.0              93 (62.8)    55 (37.2)   \<0.001
  HbSS in steady state   25.5±9.7               110 (52.9)   98 (47.1)   \<0.05
  HbSC in steady state   34.9±14.1              30 (36.6)    52 (63.4)   \<0.001
  HbSS in VOC            26.2±9.4               64 (41.0)    92 (59.0)   \<0.05
  HbSC in VOC            32.4±12.0              12 (35.3)    22 (64.7)   \<0.001
  HbSS in post VOC       26.3±9.5               15 (44.1)    19 (55.9)   \<0.05
  HbSS with leg ulcer    27.9±5.6               14 (66.7)    7 (33.3)    \<0.001
  HbSS with priapism     30.9±13.0              11 (100)     0 (0)       \<0.001

**Abbreviations:** SCD, sickle cell disease; VOC, vaso-occlusive crisis.

###### 

Plasma NOx levels in SCD sub-phenotypes and comparison group

  SCD category        NOx levels (µMol/L)   SCD category        NOx levels (µMol/L)   *P*-value
  ------------------- --------------------- ------------------- --------------------- -----------
  **Mean ± SD**                             **Mean ± SD**                             
  HbAA Comparison     59.66±0.75            HbSS steady state   46.62±0.06            0.02
  HbSS steady state   46.62±0.06            HbSS VOC            6.08±0.81             \<0.001
  HbSS VOC            6.08±0.81             HbSS post VOC       50.97±1.68            \<0.001
  HbSS post VOC       50.97±1.68            HbSS steady state   46.62±0.06            0.0216
  HbSS VOC            6.08±0.81             HbSC VOC            14.73±1.09            \<0.001
  HbSS priapism       28.97±1.27            HbSS leg ulcer      21.70±1.18            \<0.001

**Notes:** *P*\<0.001= highly significant. *P*\<0.05= significant.

**Abbreviations:** NOx, nitric oxide metabolite; SCD, sickle cell disease; VOC, vaso-occlusive crisis.
